While controversy around the US approval of Biogen’s beta-amyloid targeting Aduhelm rumbles on, its partner Ionis Pharmaceuticals has produced positive early-stage data from another Alzheimer’s candidate this time targeting tau, BIIB080.
Alongside beta amyloid, tau is the other key protein implicated in the disease, but over the years has seen similarly high numbers of failed drug candidates aimed at slowing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?